Invivogen
Menu

LPS-EB VacciGrade™

LPS-EB VacciGrade™ Unit size Cat. code Docs Qty Price
Lipopolysaccharide from E. coli 0111:B4 strain - TLR4-based adjuvant
5 x 10e6 EU
vac-3pelps
+-
$359.00

Lipopolysaccharide from E. coli 0111:B4 strain - TLR4-based adjuvant

LPS-EB VacciGrade™ is a preclinical grade preparation of lipopolysaccharide (LPS) from E. coli 0111:B4 strain. It is prepared under strict aseptic conditions.

Lipopolysaccharide (LPS) is a natural adjuvant synthesized by gram-negative bacteria and is a potent activator of the immune system. LPS stimulates the immune response through Toll-like receptor 4 (TLR4).

Similar to other TLR-based adjuvants, LPS drives Th1 immunity, although in certain circumstances low-dose inhaled LPS can promote Th2 responses. While LPS is a potent adjuvant, its pyrogenic activity has prevented clinical use of LPS in vaccines.

Most LPS preparations on the market are contaminated by other bacterial components, such as lipoproteins, thus activating TLR2 signaling as well as TLR4 signaling. LPS-EB VacciGrade™ only activates the TLR4 pathway.

Back to the top

Specifications

Species: Escherichia coli 0111:B4 strain

Specificity: Th1 response

Quality: Sterile

Working concentration: 0.1 - 25 µg/mouse

Solubility: physiological water

Quality control:

  • Preclinical grade preparation of lipopolysaccharide (LPS) from E. coli 0111:B4 strain. Prepared under strict aseptic conditions. Guaranteed sterile.
  • Presence of other bacterial components is controlled using HEK-Blue™ TLR2 cells
  • Endotoxin level is measured using a chromogenic LAL assay and the TLR4 activity is assessed using HEK-Blue™ TLR4 cells.
     
Back to the top

Contents

LPS-EB VacciGrade™ is provided lyophilized.

  • 5 x 10e6 EU of VacciGrade™ lipopolysaccharide from E. coli 0111:B4 (LPS- EB VacciGrade™)
    Note: LPS-EB VacciGrade™ is sterile filtered prior to lyophilization.
  • 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

room temperature LPS-EB VacciGrade™ is shipped at room temperature.

store Store at -20°C.

stable Product is stable 1 year when properly stored.

Upon resuspension, prepare aliquots of LPS-EB VacciGrade™ and store at -20°C.
Resuspended product is stable 6 months when properly stored.
Avoid repeated freeze-thaw cycles

Back to the top

Description

Lipopolysaccharide (LPS) is a natural adjuvant synthesized by gram-negative bacteria and is a potent activator of the immune system. LPS stimulates the immune response through Toll-like receptor 4 (TLR4) [1].

This recognition involves the binding of LPS with lipopolysaccharide-binding protein (LBP) and subsequently with CD14 which physically associates with a complex including TLR4 and MD2 [2]. Formation of the TLR4-centered LPS receptor complex induces the production of proinflammatory cytokines, such as IL-12 and TNF-α, through the MyD88 pathway.
LPS signaling also involves a MyD88-independent cascade that mediates the expression of IFN-inducible genes.

Similar to other TLR-based adjuvants, LPS drives Th1 immunity [3, 4], although in certain circumstances low-dose inhaled LPS can promote Th2 responses [5]. While LPS is a potent adjuvant, its pyrogenic activity has prevented clinical use of LPS in vaccines. Large quantities of LPS induce the overproduction of cytokines causing septic shock [1].
Intramuscular injection with LPS-EB induced the secretion of the proinflammatory cytokines TNF-α and IL-6 and the Th1-type cytokines, IFN- γ and IL-12 [6]. Cellular assays confirmed that LPS-EB is a potent inducer of dendritic cells activation and maturation via a TLR4 signaling pathway [6].

Most LPS preparations on the market are contaminated by other bacterial components, such as lipoproteins, thus activating TLR2 signaling as well as TLR4 signaling. LPS-EB VacciGrade™ only activates the TLR4 pathway.

 

1. Poltorak A. et al., 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 282(5396): 2085-8.
2. Shimazu R. et al., 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med, 189(11):1777-82.
3. Jamalan M. et al., 2011. Effectiveness of Brucella abortus lipopolysaccharide as an adjuvant for tuberculin PPD. Biologicals: journal of the International Association of Biological Standardization. 39(1); 23-28.
4. Barton G.M. & MedzhitovR., 2002. Control of adaptive immune responses by Toll-like receptors. Curr. Opin. Immunol. 14:380.
5. Iwasaki A. & Medzhitov R., 2004. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 5(10):987-95.
6. Han J. et al., 2014. Characterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-o-acylated lipooligosaccharide. PLoS One. 22;9(1):e85838.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty